Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Researchers at Mayo Clinic are investigating why multiple myeloma is the most common cancer in the Black community.

In the beginning, when I was very young, I was more interested in acute leukaemia and the suffering of young people. When I ...

A local cancer survivor, Robert Dames, has released a new book titled "Cancer - What Now" to assist others in navigating the ...

Multiple myeloma is most common in people age 65 and older. The average age of diagnosis is 70, with fewer than 1% of cases diagnosed in people younger than 35.

Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have ...

IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced ...

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...